- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Considerations & Factors For Initiating & Switching Antipsychotic Medications In Schizophrenia

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Considerations & Factors For Initiating & Switching Antipsychotic Medications In Schizophrenia
This is a Virtual Event for PsychU members in New Jersey and New York.
In this presentation, the objectives are to:
- Discuss factors to consider when initiating and switching antipsychotic treatments in schizophrenia
- Review pharmacological and pharmacokinetic considerations
- Discuss antipsychotic treatment switching strategies in schizophrenia
- Identify potential steps in implementing a change in treatment regimen

Salvatore G. Savatta, MD
Chair of Psychiatry, Trinitas Regional Medical Center, Elizabeth, NJ
More

Becky Wong, PharmD, MBA
Medical Science Director

Brijesh Patel, PharmD
Medical Science Liaison
Speaker Salvatore G. Savatta, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc.
Speakers Becky Wong, PharmD, MBA and Brijesh Patel, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.